Tumor markers in hypertensive disorders of pregnancy.

Plasma levels of tumor markers (CEA, TPA, CA 15.3, CA 125, alpha-fetoprotein) for 50 patients with hypertensive disorders of pregnancy were compared with those of 50 healthy women with singleton pregnancies and 50 healthy non-pregnant controls. With the exception of CEA all tumor marker values were higher in pregnant women, these differences being statistically significant (all p < 0.0001). Alpha-fetoprotein was lower in hypertensive than in healthy pregnant women (p = 0.0004), whereas CEA, CA 15.3 and CA 125 showed no statistically significant differences. TPA values in patients with hypertensive disorders of pregnancy (median 190 U/l) were 2.7 times higher than those of healthy pregnant controls (median 70.5 U/l) with a statistically significant difference (p < 0.0001). The individual degrees of disease severity demonstrated increasing TPA medians (pregnancy-induced hypertension: 106.5 U/l; pre-eclampsia: 200 U/l; HELLP syndrome: 339 U/l). TPA levels correlated positively with clinical severity of disease and negatively with fetal (rs = -0.58; p < 0.0001) and placental weight (rs = 0.44; p = 0.01).

[Cellular immunity in pregnancy-induced hypertensive diseases]. / Zellvermittelte Immunität bei schwangerschaftsinduzierten Hochdruckerkrankungen.

Cytokines (IL-1, sIL-2R, IL-3, IL-6, TNF-alpha, IFN-gamma, GM-CSF and neopterin) were measured in sera of 37 patients with hypertensive disorders of pregnancy, 10 healthy pregnant and 10 healthy non-pregnant controls. With the exception of neopterin (p = 0.004) there were no statistically significant differences in cytokine concentrations between healthy pregnant and non-pregnant controls. No statistically relevant differences between healthy pregnant women and hypertensive patients could be found in cytokines of T-lymphocytic origin except GM-CSF in patients with HELLP syndrome (p = 0.02). Elevated levels of IL-6, TNF-alpha and neopterin were observed in hypertensive women. Differences to healthy pregnant controls were statistically significant for IL-6 (p = 0.008), TNF-alpha (p = 0.009) and neopterin (p = 0.04) and were more pronounced in severe forms of the disease. These 3 parameters of monocytic origin showed significant positive correlations amongst each other. A participation of cell-mediated immunity (especially monocytes/macrophages) in the pathomechanism of hypertensive disorders of pregnancy can thus be assumed.

[Placental protein 12 (PP 12) in pregnancy-induced hypertensive diseases]. / Plazentares Protein 12 (PP 12) bei schwangerschaftsinduzierten Hochdruckerkrankungen.

Placental protein 12 (PP12) was measured in 30 patients with hypertensive disorders of pregnancy, 10 healthy pregnant and 10 healthy nonpregnant controls. Differences in PP12-concentrations of healthy nonpregnant (median 2.0 micrograms/l, range 1.0-5.5 micrograms/l) and healthy pregnant controls (median 110 micrograms/l, range 29-280 micrograms/l), as well as between healthy nonpregnant controls and hypertensive patients (median 125 micrograms/l, range 28-420 micrograms/l) were both statistically highly significant (p less than 0.001). The comparison between healthy pregnant and hypertensive women demonstrated no statistically significant differences. In coexistent intrauterine growth retardation (median 163 micrograms/l, range 60-400 micrograms/l), higher values could be observed in some patients, but this group showed no statistically significant difference compared to healthy pregnant controls with adequate fetal weight. PP12 does not seem to be a clinically usable parameter in the diagnosis of hypertensive disorders of pregnancy and fetal growth retardation, because of the widespread range of results.

Hemolysis in hypertensive disorders of pregnancy.

The hemolysis markers LDH, haptoglobin, bilirubin (serum, urine), urobilinogen (urine), fragmentocytes and free hemoglobin were compared in 166 patients with various degrees of hypertensive disorders of pregnancy and 179 nonhypertensive pregnant controls in a weekly screening program. Early recognition of hemolysis was limited to a period of 1 week before the actual delivery date. In the diagnostic sensitivity, haptoglobin and to a lesser degree unspecific LDH were clearly superior to the other hemolysis parameters. A decreasing platelet count also has to be taken as an indicator of impending hemolysis. Subclinical hemolysis was associated with poorer fetomaternal outcome. With the aid of haptoglobin, LDH and thrombocytes, an incipient HELLP syndrome could be recognized 1-2 days before the complete clinical picture became apparent.

Low-dose aspirin in primigravidae with positive roll-over test.

In a prospective, randomized, double-blind study for the prevention of pregnancy-induced hypertension and preeclampsia, 41 primigravidae with positive roll-over test (28th-32nd week of pregnancy) received 80 mg aspirin/day or placebo until the end of the 37th week. In the patients treated with acetylsalicylic acid (n = 22), 3 cases of proteinuria occurred, but no hypertensive pregnancy complication. In the placebo group (n = 19), 10 patients developed pregnancy-induced hypertension (6 of them preeclampsia). Group-specific differences concerning the occurrence of hypertension were statistically highly significant (p = 0.0004). No relevant differences were observed with regard to pregnancy duration, birth weight and umbilical artery pH value. The placebo group included 1 intrauterine death. No increased tendency to maternal or fetal bleeding was noticed.